TD Cowen analyst Tyler Van Buren has maintained their neutral stance on KROS stock, giving a Hold rating yesterday.
Tyler Van Buren’s rating is based on several strategic and clinical developments at Keros Therapeutics. The company has shown promising Phase I data for KER-065, which demonstrated improvements in body composition and bone density, paving the way for a potential Phase II trial in Duchenne Muscular Dystrophy (DMD) by early 2026. However, the path forward is not entirely clear due to uncertainties surrounding the halted TROPOS trial in Pulmonary Arterial Hypertension (PAH), which was terminated due to adverse events.
Additionally, Keros is in the process of evaluating strategic alternatives to enhance shareholder value, with updates expected by mid-June. These factors contribute to a cautious outlook, leading to a Hold rating as the company navigates these developments and seeks clarity on its future direction.